Decoding 4 Analyst Evaluations For Guardant Health
Portfolio Pulse from Benzinga Insights
Guardant Health (NASDAQ:GH) received mixed analyst ratings in the latest quarter, with 2 bullish and 2 somewhat bullish ratings. The average 12-month price target is now $37.75, down from $47.00. Analysts from Goldman Sachs, Raymond James, and Morgan Stanley adjusted their price targets and ratings, reflecting changes in market conditions and company performance. Guardant Health is known for its liquid-based cancer tests and has shown a revenue growth rate of 21.83% as of September 30, 2023. However, the company faces challenges with a net margin of -60.2%, ROE of -33.05%, ROA of -4.73%, and a high debt-to-equity ratio of 5.95.
January 30, 2024 | 5:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Guardant Health received mixed analyst ratings with a decreased average price target. The company shows strong revenue growth but faces profitability and debt management challenges.
The mixed analyst ratings and lowered price target suggest uncertainty, which could lead to a neutral short-term impact on GH's stock price. The strong revenue growth is positive, but concerns about profitability and high debt may offset investor sentiment.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100